Literature DB >> 35231480

Invasive Procedures and Associated Complications After Initial Lung Cancer Screening in a National Cohort of Veterans.

Eduardo R Núñez1, Tanner J Caverly2, Sanqian Zhang3, Mark E Glickman4, Shirley X Qian5, Jacqueline H Boudreau5, Donald R Miller5, Renda Soylemez Wiener6.   

Abstract

BACKGROUND: Little is known about rates of invasive procedures and associated complications after lung cancer screening (LCS) in nontrial settings. RESEARCH QUESTION: What are the frequency of invasive procedures, complication rates, and factors associated with complications in a national sample of veterans screened for lung cancer? STUDY DESIGN AND METHODS: We conducted a retrospective cohort analysis of veterans who underwent LCS in any Veterans Health Administration (VA) facility between 2013 and 2019 and identified veterans who underwent invasive procedures within 10 months of initial LCS. The primary outcome was presence of a complication within 10 days after an invasive procedure. We conducted hierarchical mixed-effects logistic regression analyses to determine patient- and facility-level factors associated with complications resulting from an invasive procedure.
RESULTS: Our cohort of 82,641 veterans who underwent LCS was older, more racially diverse, and had more comorbidities than National Lung Screening Trial (NLST) participants. Overall, 1,741 veterans (2.1%) underwent an invasive procedure after initial screening, including 856 (42.3%) bronchoscopies, 490 (24.2%) transthoracic needle biopsies, and 423 (20.9%) thoracic surgeries. Among veterans who underwent procedures, 151 (8.7%) experienced a major complication (eg, respiratory failure, prolonged hospitalization) and an additional 203 (11.7%) experienced an intermediate complication (eg, pneumothorax, pleural effusion). Veterans who underwent thoracic surgery (OR, 7.70; 95% CI, 5.48-10.81), underwent multiple nonsurgical procedures (OR, 1.49; 95% CI, 1.15-1.92), or carried a dementia diagnosis (OR, 3.91; 95% CI, 1.79-8.52) were more likely to experience complications. Invasive procedures were performed less often than in the NLST (2.1% vs 4.2%), but veterans were more likely to experience complications after each type of procedure.
INTERPRETATION: These findings may reflect a higher threshold to perform procedures in veteran populations with multiple comorbidities and higher risks of complications. Future work should focus on optimizing the identification of patients whose chance of benefit likely outweighs the complication risks.
Copyright © 2022 American College of Chest Physicians. All rights reserved.

Entities:  

Keywords:  complications; lung cancer screening; procedures; veterans

Mesh:

Year:  2022        PMID: 35231480      PMCID: PMC9424329          DOI: 10.1016/j.chest.2022.02.031

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   10.262


  44 in total

1.  Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.

Authors:  Paul F Pinsky; David S Gierada; William Black; Reginald Munden; Hrudaya Nath; Denise Aberle; Ella Kazerooni
Journal:  Ann Intern Med       Date:  2015-04-07       Impact factor: 25.391

2.  Lung Cancer Screening in a Safety-Net Hospital: Implications of Screening a Real-World Population versus the National Lung Screening Trial.

Authors:  Jonathan M Iaccarino; Katrina A Steiling; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2018-12

3.  Comparison of methods for estimating the intraclass correlation coefficient for binary responses in cancer prevention cluster randomized trials.

Authors:  Sheng Wu; Catherine M Crespi; Weng Kee Wong
Journal:  Contemp Clin Trials       Date:  2012-05-22       Impact factor: 2.226

4.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

5.  Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting.

Authors:  Jinhai Huo; Ying Xu; Tommy Sheu; Robert J Volk; Ya-Chen Tina Shih
Journal:  JAMA Intern Med       Date:  2019-03-01       Impact factor: 21.873

Review 6.  Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation.

Authors:  Linda L Humphrey; Mark Deffebach; Miranda Pappas; Christina Baumann; Kathryn Artis; Jennifer Priest Mitchell; Bernadette Zakher; Rongwei Fu; Christopher G Slatore
Journal:  Ann Intern Med       Date:  2013-09-17       Impact factor: 25.391

7.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

8.  Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort.

Authors:  Mamta Ruparel; Samantha L Quaife; Jennifer L Dickson; Carolyn Horst; Sophie Tisi; Helen Hall; Magali N Taylor; Asia Ahmed; Penny J Shaw; Stephen Burke; May-Jan Soo; Arjun Nair; Anand Devaraj; Karen Sennett; John R Hurst; Stephen W Duffy; Neal Navani; Angshu Bhowmik; David R Baldwin; Sam M Janes
Journal:  Ann Am Thorac Soc       Date:  2020-07

9.  A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results.

Authors:  Tessa Kennedy-Martin; Sarah Curtis; Douglas Faries; Susan Robinson; Joseph Johnston
Journal:  Trials       Date:  2015-11-03       Impact factor: 2.279

10.  Adherence to Follow-up Testing Recommendations in US Veterans Screened for Lung Cancer, 2015-2019.

Authors:  Eduardo R Núñez; Tanner J Caverly; Sanqian Zhang; Mark E Glickman; Shirley X Qian; Jacqueline H Boudreau; Christopher G Slatore; Donald R Miller; Renda Soylemez Wiener
Journal:  JAMA Netw Open       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.